Major investment for Sanofi Pasteur
Sanofi Pasteur, a part of the French drug giant Sanofi-Aventis, expects to have completed investment of 200.0 million euros ($270.9 million) by 2009 in order to double vaccine production capacity at its Val-de-Reuil plant in the Eure department of France. The project includes several new vaccine formulation lines.
Val-de-Reuil is now the world's leading site for influenza vaccines output, with some 120 million doses produced in 2006. Last year, the unit also produced 1.4 million vaccines doses for the treatment of the H5N1 virus under a government contract.
Major center for pharma
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze